SEC Form 4 · accession 0001190725-16-000428
Mirati Therapeutics, Inc. · MRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Officer — PRESIDENT & CEO · Director
Period of report
Jun 14, 2016
Accepted (ET)
Jun 14, 2016 · 3:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001576263
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 14, 2016 | P | 20,000 | $7.0535 | A | 48,556 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.96 to $7.14, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.